{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:33:25Z","timestamp":1791297205533,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.eururo.2011.08.041","type":"journal-article","created":{"date-parts":[[2011,8,29]],"date-time":"2011-08-29T15:20:07Z","timestamp":1314631207000},"page":"1244-1250","source":"Crossref","is-referenced-by-count":96,"title":["Androgen-Deprivation Therapy and the Risk of Stroke in Patients With Prostate Cancer"],"prefix":"10.1016","volume":"60","author":[{"given":"Laurent","family":"Azoulay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Benayoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.08.041_bib0005","first-page":"293","article-title":"The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.08.041_bib0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijir.3901471","article-title":"Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy","volume":"18","author":"Braga-Basaria","year":"2006","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.eururo.2011.08.041_bib0015","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.08.041_bib0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2011.08.041_bib0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","article-title":"Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer","volume":"71","author":"Smith","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.08.041_bib0030","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer","volume":"63","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.08.041_bib0035","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.08.041_bib0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2011.08.041_bib0045","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden","volume":"28","author":"Van","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.08.041_bib0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/95.13.981","article-title":"National practice patterns and time trends in androgen ablation for localized prostate cancer","volume":"95","author":"Cooperberg","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2011.08.041_bib0055","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(97)04248-7","article-title":"The UK General Practice Research Database","volume":"350","author":"Walley","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2011.08.041_bib0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2125.1998.00701.x","article-title":"Use of the UK General Practice Research Database for pharmacoepidemiology","volume":"45","author":"Garcia Rodriguez","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eururo.2011.08.041_bib0065","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/bmj.302.6779.766","article-title":"Validation of information recorded on general practitioner based computerised data resource in the United Kingdom","volume":"302","author":"Jick","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2011.08.041_bib0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/pubmed\/21.3.299","article-title":"Clinical information for research; the use of general practice databases","volume":"21","author":"Lawrenson","year":"1999","journal-title":"J Public Health Med"},{"key":"10.1016\/j.eururo.2011.08.041_bib0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-2125.2000.00199.x","article-title":"Validation of the diagnosis of venous thromboembolism in general practice database studies","volume":"49","author":"Lawrenson","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eururo.2011.08.041_bib0080","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1592\/phco.23.5.686.32205","article-title":"Validity of the general practice research database","volume":"23","author":"Jick","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eururo.2011.08.041_bib0085","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(97)80084-0","article-title":"Calcium-channel blockers and risk of cancer","volume":"349","author":"Jick","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2011.08.041_bib0090","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1212\/01.WNL.0000110312.36809.7F","article-title":"Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice","volume":"62","author":"Hall","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.eururo.2011.08.041_bib0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/pros.20341","article-title":"Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer","volume":"66","author":"Kaku","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2011.08.041_bib0100","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.urology.2007.09.066","article-title":"Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer","volume":"71","author":"Bong","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.08.041_bib0105","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.08.041_bib0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1078-1439(03)00016-4","article-title":"The timing of hormone therapy for men with asymptomatic advanced prostate cancer","volume":"21","author":"Messing","year":"2003","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2011.08.041_bib0115","article-title":"Early versus deferred androgen suppression in the treatment of advanced prostatic cancer","author":"Nair","year":"2002","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811009092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811009092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T11:50:28Z","timestamp":1543578628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811009092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0302283811009092"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.08.041","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}